https://nevro.com/generated by Q4Tue, 21 Apr 2026 12:23:33 -0400Copyright Q4 Inc. All rights reserved.821dbfd8-179f-4afc-bc33-f9c08ad09685https://nevro.com/English/us/investors/investor-news/investor-news-details/2025/Globus-Medical-completes-acquisition-of-Nevro-Corp-/default.aspxThu, 03 Apr 2025 00:00:00 -0400a1bf9fdc-b537-4b91-8da4-bddf7c2e0adbhttps://nevro.com/English/us/investors/investor-news/investor-news-details/2025/Nevro-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results/default.aspxTue, 04 Mar 2025 16:15:00 -050094843ee1-6dde-4d4e-95f6-5184745d4d25https://nevro.com/English/us/investors/investor-news/investor-news-details/2025/Globus-Medical-to-Acquire-Nevro-Corp.to-Expand-Treatment-Options-for-Patients/default.aspxThu, 06 Feb 2025 09:30:00 -050054756a70-bea3-4d1c-8bb3-7ab1b2b0cb20https://nevro.com/English/us/investors/investor-news/investor-news-details/2025/Nevro-Announces-New-Employee-Inducement-Grants-Under-NYSE-Rule-303A.08/default.aspxTue, 21 Jan 2025 16:30:00 -0500c6a69455-156d-4bcb-bfad-d2c6a2ba39c1https://nevro.com/English/us/investors/investor-news/investor-news-details/2025/Nevro-Announces-Preliminary-Fourth-Quarter-and-Full-Year-2024-Revenue-Results/default.aspxMon, 13 Jan 2025 08:30:00 -05003288bbcc-a6cf-451d-a181-7a44bf50c164https://nevro.com/English/us/investors/investor-news/investor-news-details/2024/Nevro-Announces-New-Employee-Inducement-Grants-Under-NYSE-Rule-303A.08-a7dfcc244/default.aspxTue, 17 Dec 2024 16:30:00 -05000183bfe4-8ea3-44ac-b69a-df9b930108edhttps://nevro.com/English/us/investors/investor-news/investor-news-details/2024/New-Study-Demonstrates-Multiple-Advantages-of-Nevro1-the-Novel-SI-Joint-Fusion-System-by-Nevro-in-Comparison-to-Posterolateral-and-Lateral-Approaches/default.aspxMon, 18 Nov 2024 08:30:00 -0500df379834-bbbc-4b31-a741-2bd9ba653858https://nevro.com/English/us/investors/investor-news/investor-news-details/2024/Nevro-Announces-New-Employee-Inducement-Grants-Under-NYSE-Rule-303A.08-2c8816939/default.aspxFri, 15 Nov 2024 08:30:00 -050080bd43bb-59cc-4d68-b0b2-ecd36f245bb7https://nevro.com/English/us/investors/investor-news/investor-news-details/2024/Nevros-HFX-iQ-Spinal-Cord-Stimulation-with-AI-Technology-Receives-CE-Mark-Certification-in-Europe-Increasing-Product-Expansion-Globally/default.aspxTue, 12 Nov 2024 07:00:00 -0500091c398f-9c56-419c-aad0-0ab4ee04efb7https://nevro.com/English/us/investors/investor-news/investor-news-details/2024/Nevro-Reports-Third-Quarter-2024-Financial-Results/default.aspxMon, 11 Nov 2024 16:05:00 -0500